COCP Company Financial Information

Symbol Info
Cocrystal Pharma Inc. (COCP)
Listed Symbol	COCP
Name	Cocrystal Pharma Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share	$-
Latest Fiscal Date	2018-12-31
Latest Fiscal Revenue	$-
Latest Fiscal EPS	$-1.75
Price Info
21 Day Moving Average	$2.0585
21 Day EMA	$2.006970
50 Day Moving Average	$2.1760
50 Day EMA	$2.147370
200 Day EMA	$2.596020
200 Day Moving Average	2.660260
52 Week High	$5.28
52 Week Low	$1.51
52 Week Change	$-33.695700
Alpha	-0.000539
Beta	0.8383
Standard Deviation	0.283811
R2	0.010367
Periods	60
Share Information
10 Day Average Volume	9,519
20 Day Average Volume	7,926
30 Day Average Volume	6,926
50 Day Average Volume	5,629
Outstanding Shares	31,620,646
Float Shares	-
Percent Float	-
Short Interest	-
Short Percent Float	-
Short Interest Ratio	-
Short Date
Holders
Institutions	35
Institute Holdings Date	2019-08-31
Institute Bought Previous 3 Months	119,643
Institute Holdings Percent	14.300000
Institute Sold Previous 3 Months	26,758
Insider Holdings Date	2018-05-31
Insider Bought Previous 3 Months	799,367
Insider Holdings Percent	-
Insider Sold Previous 3 Months	-
Insiders Shares Owned	312,248,918
Price Change
7 Day Price Change	$0.0200001
7 Day Percent Change	1.11%
21 Day Price Change	$-0.3698999
21 Day Percent Change	-16.81%
30 Day Price Change	$-0.5083998
30 Day Percent Change	-21.74%
Month To Date Price Change	$-0.46
Month To Date Percent	-20.09%
90 Day Price Change	$-0.37
90 Day Percent Change	-16.82%
Quarter To Date	$-0.52
Quarter To Date Percent	-22.13%
180 Day Price Change	$-1.07
180 Day Percent Change	-36.90%
200 Day Price Change	$-1.07
200 Day Percent Change	-36.90%
Year To Date	$-1.77
Year To Date Percent	-49.17%
Profile
Description	Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.
Details
Issue Type	CS
Market Cap	$57,865,782
Sec Type	EQS
Auditor	BDO USA, LLP
Total Shares Outstanding	31,620,646
CEO	Gary L. Wilcox
Employees	10
Last Audit	UE
Classification
CIK	0001412486
Industry	Biotechnology
Sector	Healthcare
NAICS	Pharmaceutical Preparation Manufacturing(325412)
Info
Address	19805 North Creek Parkway Bothell, WA 98011
Website	http://www.cocrystalpharma.com
Facisimile
Telephone	+1 786 459-1831
Email	cocp@jtcir.com
Key Ratios
Profitability
EBIT Margin	-1,012.3
EBITDA Margin	-1,009.8
Pre-Tax Profit Margin	-
Profit Margin Cont	-
Gross Margin	-
Profit Margin TOT	-
Income Statements
Revenue	$5,670,000
Revenue Per Share	$0.1793
Revenue 3 Years	$-
Revenue 5 Years	$-
Valuation Measures
PE Ratio	-
Enterprise Value	$51,396,782
Price To Sales	10.205606
Price To Free Cash	-18.2
PE High Last 5 Years	-
Price To Book	0.8
Price To Cash Flow	54.7
PE Low Last 5 Years	-
Price To Tangible Book	8.0
Financial Strength
Total Debt To Equity	0.0
Int Coverage	-
Current Ratio	4.6
Leverage Ratio	1.1
Quick Ratio	4.5
Long Term Debt To Capital	0.01
Assets
Receivables Turnover	3.2
Invoice Turnover	-
Assets Turnover	-
Management Effectiveness
Return Assets	-44.42
Return On Equity	-48.3
Return On Capital	-47.78
Dividends
Dividend 3 Years	$-
Dividend 5 Years	$-
Ex Dividend Date
Dividend Rate	$-
Dividend Yield	-
Payment Type